QuantideX® qPCR PML-RARA Kit*✝
Sensitive and Scalable Detection of Three PML-RARA Primary Fusion Transcripts
The QuantideX® qPCR PML-RARA Kit* offers sensitive and scalable detection of three PML-RARA aberrant fusions in a single, multiplex RT-qPCR reaction, with results in less than five hours. Bcr1, bcr2, and bcr3 aberrant fusions of the PML-RARA, these fusions are crucial indicators of acute promyelocytic leukemia (APL), a distinct and aggressive subtype of acute myeloid leukemia (AML).
The QuantideX qPCR-PML-RARA Kit’s multiplex design reduces complexity and hands-on time.
Reduced Complexity
- One reaction for three PML-RARA breakpoints (bcr1/bcr2/bcr3)
- Ready-to-use design with all necessary RT-qPCR reagents, controls, and calibrators
- Compatible with common laboratory equipment
Optimized Workflow
- Multiplex reactions allow detection of three primary fusion transcripts of PML-RARA and the reference gene in one well
- Automated data reporting software and data analysis
Quality Results
- Four calibrators included
- Highly sensitive limit of detection (LOD)
Figure 1. Comparison of plate layout for an 8 sample run between the (a) Multiplex Asuragen assay, with samples run in singlicate, resulting in only 19 reactions; and (b) a singleplex competitor assay, with samples run in duplicate, resulting in 52 reactions.
Figure 2. QuantideX qPCR PML-RARA Kit*✝ workflow
Download the QuantideX qPCR PML-RARA Kit Brochure
Scientific Poster
Prototype RT-qPCR PML::RARA Reagents and a Commercial PML-RARA Kit Yield Highly Correlated Results Walairat Laosinchai Wolf, Adrian Lara, and Justin T Brown, AMP 2023
Request More Information
Interested in becoming an EAP Site?
Disclaimers
*For research use only, not for use in diagnostic procedures.
✝This product is under development; performance characteristics and final product features to be determined.
QuantideX® qPCR PML-RARA Kit*✝
Sensitive and Scalable Detection of Three PML-RARA Primary Fusion Transcripts
The QuantideX® qPCR PML-RARA Kit* offers sensitive and scalable detection of three PML-RARA aberrant fusions in a single, multiplex RT-qPCR reaction, with results in less than five hours. Bcr1, bcr2, and bcr3 aberrant fusions of the PML-RARA, these fusions are crucial indicators of acute promyelocytic leukemia (APL), a distinct and aggressive subtype of acute myeloid leukemia (AML).
The QuantideX qPCR-PML-RARA Kit’s multiplex design reduces complexity and hands-on time.
Reduced Complexity
- One reaction for three PML-RARA breakpoints (bcr1/bcr2/bcr3)
- Ready-to-use design with all necessary RT-qPCR reagents, controls, and calibrators
- Compatible with common laboratory equipment
Optimized Workflow
- Multiplex reactions allow detection of three primary fusion transcripts of PML-RARA and the reference gene in one well
- Automated data reporting software and data analysis
Quality Results
- Four calibrators included
- Highly sensitive limit of detection (LOD)
Figure 1. Comparison of plate layout for an 8 sample run between the (a) Multiplex Asuragen assay, with samples run in singlicate, resulting in only 19 reactions; and (b) a singleplex competitor assay, with samples run in duplicate, resulting in 52 reactions.
Figure 2. QuantideX qPCR PML-RARA Kit*✝ workflow